Drug intelligence / Profile preview

NA-201

Development stage: Preclinical
Lead developer: Allero Therapeutics
Modality: Gene Silencing → Gene Therapies, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies

Overview

NA-201 is a preclinical drug candidate currently under development by Allero Therapeutics. It is characterized by a hybrid modality described as an antibody-drug conjugate (ADC) combined with gene therapy, potentially involving the targeted delivery of genetic material via an antibody-based vehicle. As of early 2024, Allero Therapeutics has not publicly disclosed the specific molecular targets, the nature of the genetic payload, or the primary therapeutic indications for this asset. The program is distinct from the company's SOMIT (Sequential Oral Mucosal Immunotherapy) platform, which focuses on oral patches for celiac disease and allergies.

Beyond the preview

Go deeper on NA-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NA-201.

Explore the full profile